From the FDA Drug Label
The following events have been reported in association with mirabegron use in worldwide postmarketing experience: Cardiac disorders: atrial fibrillation Gastrointestinal disorders: nausea, constipation, diarrhea Nervous system disorders: dizziness, headache There have been postmarketing reports of confusion, hallucinations, insomnia and anxiety in patients taking mirabegron Skin and subcutaneous tissue disorders: angioedema of the face, lips, tongue, and larynx, with or without respiratory symptoms Renal and urinary disorders: urinary retention
The long-term risks for Myrbetriq (mirabegron) include:
- Cardiac disorders: atrial fibrillation
- Nervous system disorders: dizziness, headache, confusion, hallucinations, insomnia, and anxiety
- Skin and subcutaneous tissue disorders: angioedema
- Renal and urinary disorders: urinary retention 1
From the Research
Myrbetriq (mirabegron) has been found to have a favorable safety profile with no increased risk of major adverse cardiovascular events, acute myocardial infarction, stroke, cardiovascular mortality, or all-cause mortality compared to antimuscarinic treatments for overactive bladder, as shown in a recent large-scale study 2. The most significant long-term concerns with Myrbetriq include potential cardiovascular effects such as increased blood pressure and heart rate, which could be problematic for patients with existing hypertension or heart conditions. Some key points to consider:
- Urinary retention is another possible risk, particularly in patients with bladder outlet obstruction or those taking other medications that affect urination.
- Some patients may experience liver or kidney problems with extended use, though these are relatively rare.
- Common side effects that might persist long-term include headaches, urinary tract infections, and gastrointestinal issues like constipation or nausea.
- Patients taking Myrbetriq should have regular check-ups to monitor blood pressure and assess kidney and liver function, especially during the first year of treatment, as recommended by studies such as 3 and 4. These monitoring visits allow healthcare providers to detect any developing problems early, and adjustments to treatment can be made as needed, based on the findings of studies like 5. If you experience persistent side effects or new symptoms while on Myrbetriq, it's essential to discuss them with your healthcare provider rather than discontinuing the medication abruptly, to ensure the best possible outcome in terms of morbidity, mortality, and quality of life.